John K. Clarke - 22 May 2024 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Reporting relationship: Director
Issuer ticker: ATYR
Reported as of: 22 May 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 May 2024, 19:30:40 UTC
Prior SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Nancy E. Denyes, as Attorney-in-Fact

Key filing fact

John K. Clarke filed Form 4 for aTYR PHARMA INC (ATYR) on 23 May 2024.

Key facts

This page summarizes John K. Clarke's Form 4 filing for aTYR PHARMA INC (ATYR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 May 2024, 19:30.

Change

Previous filing in this sequence was filed on 19 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIFE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +24,000
Change %
Price: $0.000000
Shares after: 24,000
Date: 22 May 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,000
Exercise price: $1.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.